Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Adds Liver Warning To Multiple Sclerosis Therapy Avonex

This article was originally published in The Pink Sheet Daily

Executive Summary

Interferon beta product joins Serono/Pfizer's Rebif with warning reflecting postmarketing experiences. Berlex' Betaseron does not have a warning but recommends testing. Coming on the heels of the Tysabri withdrawal, the labeling change is the second recent setback for Biogen Idec's multiple sclerosis franchise.

You may also be interested in...



Copaxone Reaches MS Market Share High Following Tysabri Withdrawal

Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.

Copaxone Reaches MS Market Share High Following Tysabri Withdrawal

Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.

Berlex Issues Betaseron Liver Testing Reminder Due To Increased MS Safety Focus

“Dear Health Care Professional” letter is sent to 7,000 physicians reminding them that liver function testing is recommended at one, three and six months following initiation of Betaseron for MS treatment.

Related Content

Topics

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel